Objective To quantify key disease milestones, particularly loss of ambulation and survival, and to describe the VPS13A variant spectrum and clinical heterogeneity in patients with chorea-acanthocytosis (ChA).
Methods We conducted a cross-sectional study of 34 ChA patients from 24 unrelated families. Whole-exome sequencing identified VPS13A variants in all probands. Clinical and paraclinical data were collected through neurological evaluations and electronic medical records. Patients were classified as either surviving (ambulatory or non-ambulatory) or deceased.
Results Twenty-one VPS13A variants were identified, including 12 novel variants. Median current age and disease duration were 38.5 years (interquartile range [IQR], 34–43 years) and 8.0 years (IQR, 4–12.25 years), respectively. Loss of ambulation occurred in 26.5% of patients after a median of 10 years (range, 5–16 years) from onset. Kaplan–Meier analysis estimated a median time to loss of ambulation of 16.0 years (95% confidence interval [CI], 8.8–23.2 years), with estimated ambulation probabilities of 87.4% at 6 years and 38.0% at 16 years. Seven patients died after a median disease duration of 10 years (range, 3–17 years). The median survival time was not reached during follow-up; the estimated restricted mean survival time was 16.7 years (95% CI, 14.1–19.3 years). Compulsions co-occurred with obsessions in all cases and were associated with higher rates of suicidal ideation, while insomnia was more frequent in patients without compulsions. Suicide and sepsis were the leading causes of death.
Conclusion This study defines the natural history of ChA, providing prognostic data on ambulation and survival. The discovery of novel VPS13A variants highlights genetic heterogeneity and supports further investigation into disease mechanisms and therapeutic targets.
Objective Woodhouse-Sakati syndrome (WSS) is a rare autosomal recessive neuroendocrine disorder characterized by a variety of endocrine and neurological manifestations, including extrapyramidal symptoms and intellectual disability.
Methods This report presents the genetic characterization of five Iranian patients with WSS, including the first Iranian patient to undergo deep brain stimulation (DBS).
Results We highlight five Iranian patients with mutations in the DCAF17 gene presenting with variable features of WSS, with symptom onset in early adolescence. Whole exome sequencing identified four homozygous variants (c.436delC, c.982-2A>G, c.580C>T, and c.838+1G>A) within the DCAF17 gene in the probands. Patients had variable responses to common therapies, and one patient achieved significant improvement following DBS.
Conclusion We expand the clinical and genetic heterogeneity among Iranian patients and suggest the c.436delC variant as a founder mutation in the region. We highlight the importance of considering WSS in patients with both neurological and endocrine symptoms and suggest DBS as a potential treatment option.
Citations
Citations to this article as recorded by
Clinical and Molecular Findings in Two Siblings with a Novel Homozygous DCAF17 Frameshift Variant and Review of the Literature: A Case Report Simge Tuana Ay Öner, Elif Yılmaz Güleç Molecular Syndromology.2026; : 1. CrossRef
Multidisciplinary management of concurrent hypogonadism, diabetes, and hypothyroidism in Woodhouse-Sakati syndrome: a case report and preliminary clinical management experience Xiaoyang Shi, Kai Zhang, Junpeng Yang, Ruizhi Zheng, Huijuan Yuan Rare Disease and Orphan Drugs Journal.2026;[Epub] CrossRef